Navigation Links
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
Date:7/25/2012

ROCKVILLE, Md., July 25, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study. The study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute.  More information about the clinical trial can be found at www.ClinicalTrials.gov.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

Jennifer R. Diamond, MD, stated, "Triple-negative breast cancer represents an aggressive breast cancer subtype which carries a high risk of developing distant metastasis.  It remains an area of unmet need in terms of effective anti-cancer agents with innovative patient selection strategies. We are encouraged by the data from the Phase 1 study of ENMD-2076 in patients with advanced solid tumors, including triple-negative breast cancer. ENMD-2076 has also demonstrated significant anti-tumor activity against preclinical models of breast cancer with more robust activity against triple-negative breast cancer alone or in combination with standard chemotherapies.  This single-agent Phase 2 study is designed to determine the activity of ENMD-2076 by the clinical benefit rate in patients with previously treated locally advanced or metastatic triple-negative breast cancer."

Ken Ren, Ph.D., EntreMed's Chief Executive Officer commented, "The development of ENMD-2076 to address the unmet medical need for an effective treatment of triple-negative breast cancer represents a part of our integrated initiatives in the clinical advancement of the ENMD-2076 oncology platform.
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
3. Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
4. Egalet Announces Issuance of U.S. Patent
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Sancilio and Company Announces New Directors
7. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
8. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
9. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
10. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
11. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/fw4ctl/investigation ) ... on China,s Entecavir Market, 2010-2019" report to their ... hepatitis B virus (HBV) exceeds 100 million in ... from chronic Hepatitis B. About 0.5 million Chinese is ... caused by chronic Hepatitis B, causing a loss of ...
(Date:9/3/2015)... , Sep. 03, 2015 ... addition of the "Investigation Report on China,s Raloxifene ... According to the statistics, over 200 million people suffer ... and above in China , 50% ... is 30%-50% among women aged 60 and above. ...
(Date:9/3/2015)... 2015 China,s startup ... Patch, a wearable medical device that can continuously monitor ... providing safety guidance for pregnant women. The device will ... device, which measures 4 centimeters in diameter, is as ... more than an Apple earphone cord. The small and ...
Breaking Medicine Technology:China Entecavir Market Report 2010-2019 2Investigation Report on China's Raloxifene Market, 2015-2019 2Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2
... (Nasdaq CM: INSM), a biopharmaceutical company, will host a ... AM ET, to discuss its financial results for the ... quarterly financial results press release before the market opens ... the live conference call, please dial 800-901-5213 (U.S. callers) ...
... Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that ... 31, 2012, on Thursday, May 10, 2012, following the close ... investor conference call and live webcast to discuss the financial ... Time / 2:00 p.m. Pacific Time on the same date. The ...
Cached Medicine Technology:Insmed to Host 2012 First Quarter Earnings Conference Call 2Insmed to Host 2012 First Quarter Earnings Conference Call 3Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 2Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 3
(Date:9/3/2015)... ... September 03, 2015 , ... While bariatric surgeon Michael Feiz, M.D., ... when preparing for a bariatric procedure, some patients have been recently asking further questions ... instructions typical for many types of surgery that should be followed in the days ...
(Date:9/3/2015)... ... September 03, 2015 , ... Allied Anesthesia is proud to announce a ... norm not the exception. , St. Jude was recently named one of the nation’s ... making it one of only 10 hospitals in the state to earn the distinction. ...
(Date:9/3/2015)... ... , ... TransPack Toon gives users a set of 90 cartoon transitions for ... in 30 different styles. Presets range from snow, underwater, forest, futuristic, city and many ... features 90 cartoon transitions from 30 unique styles. Editors can choose between line ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Inc. , a privately held medical technology company that will bring low-cost cancer ... markets worldwide. , Preora’s proprietary and automated technology platform detects and measures ...
(Date:9/3/2015)... Buffalo, New York (PRWEB) , ... September 03, 2015 , ... ... We Do”. William Mattar, Esq. believes this does not stop at any certain ... closed captioning to its newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , ...
Breaking Medicine News(10 mins):Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2
... A nationwide study examining the safety of Tasers ... safe, causing a low occurrence of serious injuries., This ... associated with Tasers. It is the first injury epidemiology ... assess the overall risk and severity of injuries in ...
... no significant change in the quality of care for ... Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) ... 2007 issue of CANCER, a peer-reviewed journal of the ... Friedman from the Duke Clinical Research Institute in Durham, ...
... -- Cancer patients receiving chemotherapy have not noticed a ... of the Medicare Prescription Drug, Improvement and Modernization Act ... government reimbursement to oncologists, according to a new study ... (DCRI). , Critics of the MMA often said that ...
... - Report Suggests Millions of Sports Persons are Suffering ... health reveals that men and,women who aim to keep fit, ... of all active respondents who took part in the survey ... seem to be a common occurrence for the nations top,sports ...
... recent months, a,perfect storm of new technology and research ... and genetics, writes Lee Silver, a professor,of molecular biology ... heredity is the result of an incredibly complex interplay,among ... different,genes and even the vast stretches of "junk DNA" ...
... today expressed their great disappointment in President Bushs veto ... Health Insurance Program (SCHIP). The sentiment was expressed ... by David C. Dale, MD, FACP, president of the ... the 124,000 internal medicine physicians and medical student members ...
Cached Medicine News:Health News:Nationwide independent Taser study results suggest devices are safe 2Health News:Patients perceived cancer care unaffected by lower Medicare reimbursements 2Health News:Medicare modernization act did not change chemotherapy as feared 2Health News:More Damage Than Good? Shock Survey Reveals Sport can Actually be bad for Your Joints 2Health News:More Damage Than Good? Shock Survey Reveals Sport can Actually be bad for Your Joints 3Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 2Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 3Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 4Health News:'Great disappointment' in veto of SCHIP legislation expressed by American College of Physicians 2
AxSYM Myoglobin is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of myoglobin in human serum or plasma on the AxSYM System....
... VITROS ECi brings true automation and ... testing. Highly sensitive assays for thyroid, ... bone metabolism testing are currently available, ... The VITROS ECi can simultaneously process ...
... Tests are used by hospitals, clinics and ... human health conditions. The majority of these ... which are offered in strip, cassette, and ... through membrane tests are also available. All ...
ELISA kit for detection of the cardiac marker Myoglobin. Kit features interchangeable reagents, E-Z Process performed at room temp, and results in less than 1 hour!...
Medicine Products: